

Docket No. 3086-A

Appl. No. 09/981,421
Restrict. Require. dated Aug. 9, 2004
Resp. filed Sept. 9, 2004

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. *(Currently Amended)* A method of treating a patient afflicted with a medical disorder selected from the group consisting of ~~rheumatoid arthritis and inflammatory bowel disease~~ psoriasis, renal failure due to ischemia, and viral hepatitis,
the method comprising administering to said patient a therapeutically effective amount of an ~~IL-18 antagonist~~ antibody that binds the IL-18 receptor component of
SEQ ID NO:4.
2. *(Withdrawn)* The method of Claim 1, wherein the IL-18 antagonist is soluble IL-18 receptor.
3. *(Withdrawn)* The method of Claim 2, wherein the soluble IL-18 receptor is a heterodimeric receptor.
4. *(Canceled)*
5. *(Canceled)*
6. *(Currently Amended)* The method of Claim ~~[[4]]~~1, wherein the antibody is a humanized antibody.
7. *(Original)* The method of Claim 6, wherein the antibody is a single-chain antibody.
8. *(Withdrawn)* The method of Claim 1, wherein the IL-18 antagonist is a soluble IL-18 binding protein.
9. *(Currently amended)* The method of Claim 1, wherein the ~~IL-18 antagonist~~ antibody is administered one or more times per week.

Docket No. 3086-A

Appl. No. 09/981,421
Restrict. Require. dated Aug. 9, 2004
Resp. filed Sept. 9, 2004

10. *(Currently amended)* The method of Claim 1, wherein the ~~IL-18~~ antagonist antibody is administered by subcutaneous injection.
11. *(Currently amended)* The method of Claim 1, wherein the ~~IL-18~~ antagonist antibody is administered in combination with one or more compounds selected from the group consisting of non-steroidal anti-inflammatory drugs; analgesics; systemic steroids; antagonists of inflammatory cytokines; anti-inflammatory cytokines; antibodies against T cell surface proteins; anthralin; vitamin D3 and its analogs; oral retinoids; salicylic acid; methotrexate; cyclosporine; hydroxyurea; and sulfasalazine.
12. *(Currently amended)* The method of Claim 1, wherein the ~~IL-18~~ antagonist antibody is administered in combination with a TNF inhibitor.
13. *(Original)* The method of claim 12 wherein the TNF inhibitor is TNFR:Fc.
14. *(Currently amended)* The method of Claim 1, wherein the ~~IL-18~~ antagonist antibody is administered in combination with an antagonist to a cytokine selected from the group consisting of IFN γ , TGF β , IL-6 and IL-8.
15. *(Currently amended)* The method of Claim 12 wherein the ~~IL-18~~ antagonist antibody and TNF inhibitor are administered in combination with an antagonist to a cytokine selected from the group consisting of IFN γ , TGF β , IL-6, IL-8, IL-12, and IL-15.